Comparative predictive value of immunotherapy biomarkers: a systematic review and network meta-analysis
Biomarker performance varies by cancer type and clinical context. ctDNA, PD-L1 (high thresholds, as ≥50%), and TMB are leading predictors, with combinations potentially optimizing performance. Future research must address heterogeneity and standardization to refine individualized immunotherapy strategies.
Authors
- J. J. Feng
- P. M. Huang (ORCID: https://orcid.org/0009-0009-7837-4217)
- Nuerye Tuerhong
- Feng Wen (ORCID: https://orcid.org/0009-0009-6203-0559)
- Qiu Li
- Benqi He
- Yang Yang
Institutions
- Sichuan University (CN)
- West China Medical Center of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
- Lanzhou University Second Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1097/js9.0000000000004588
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05